139183-98-5

Basic information

• Product Name: 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLIC ACID METHYL ESTER
• Synonyms: 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLIC ACID METHYL ESTER;Methyl 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-carboxylate;Methyl iMidazo[1,2-a]piperidine-6-carboxylate;methyl 5H,6H,7H,8H-imidazo[1,2-a]pyridine-6-carboxylate;5,6,7,8-Tetrahydro-imidazo[1,2-a]pyridine-6-carboxylic acid
• CAS NO: 139183-98-5
• Molecular Formula: C9H12N2O2
• Molecular Weight: 180.206
• Mol File: 139183-98-5.mol

Chemical Properties

• Boiling Point: 340.9±35.0 °C(Predicted)
• Appearance: /
• Density: 1.29
• PKA: 7.16±0.40(Predicted)
• CAS DataBase Reference: 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLIC ACID METHYL ESTER(139183-98-5)
• EPA Substance Registry System: 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLIC ACID METHYL ESTER(139183-98-5)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 139183-98-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLIC ACID METHYL ESTER is used as a research compound for its potential therapeutic applications, particularly in the development of treatments for neurological disorders and cancer. Its ability to modulate cellular processes makes it a promising candidate for further investigation and development.
Used in Neurological Disorders Treatment:
In the field of neurology, 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLIC ACID METHYL ESTER is used as a potential treatment for neurological disorders due to its capacity to influence specific cellular mechanisms that may be implicated in such conditions.
Used in Cancer Treatment:
In oncology, 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLIC ACID METHYL ESTER is used as a potential anticancer agent, with preclinical studies indicating its potential to impact cancer cell behavior and contribute to cancer treatment strategies.
Used as a Synthesis Intermediate:
5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDINE-6-CARBOXYLIC ACID METHYL ESTER is also used as an intermediate in the synthesis of other biologically active compounds, highlighting its versatility and importance in the creation of new pharmaceuticals and therapeutic agents.

Upstream product

• 136117-69-6 methyl 6-imidazo<1,2-a>pyridinecarboxylate 

Downstream Products

• 139183-99-6 Hydrochloride of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-carboxylic acid 

Relevant articles and documents

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. I. Synthesis and structure-activity relationships of conformationally restricted fused imidazole derivatives

We prepared a novel series of conformationally restricted fused imidazole derivatives 4b, 4c and 4d (possessing 4,5,6,7-tetrahydroimidazo[4,5- c]pyridine and substituted 4,5,6,7-tetrahydro-1H-benzimidazole for 4b, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine for 4c and 5,6,7,8- tetrahydroimidazo[1,5-a]pyridine for 4d as a basic amine part and (2- methoxyphenyl)aminocarbonyl group as an aromatic-carbonyl part). Their activities were then evaluated as an 5-hydroxytryptamine (5-HT3) receptor antagonist which may be useful for the treatment of irritable bowel syndrome (IBS) as well as for nausea and vomiting associated with cancer chemotherapy. The most potent compound was N-(2-methoxyphenyl)-4,5,6,7-tetrahydro-1H- benzimidazole-5-carboxamide 14 in this series with an ID50 value of 0.32 μg/kg on the von Bezold-Jarisch reflex in rats and an IC50 value of 0.43 μM on the isolated colonic contraction in guinea pig, approximately ten and two times more potent than ondansetron 1, respectively. The structure- activity relationships (SAR) study suggested that the high potency of 14 may be attributed to the suitable position and direction of the N-C-N centroid in the conformationally restricted imidazole ring against the planar (2-methoxy- phenyl)aminocarbonyl part in the binding of 14 to the receptor.